Mobile

A randomized, double-blind, cross-over, 4-period, 4 treatment, within-subject placebo-controlled study to assess the optimal renoprotective dose of Aliskiren in hypertensive type 2 diabetes patients w...

Update Il y a 4 ans
Reference: EUCTR2005-000286-19

A randomized, double-blind, cross-over, 4-period, 4 treatment, within-subject placebo-controlled study to assess the optimal renoprotective dose of Aliskiren in hypertensive type 2 diabetes patients with incipient or overt nephropathy

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

• Investigate the antiproteinuric effect of increasing dose administration of Aliskiren versus Aliskiren matching placebo

Inclusion criteria

  • Hypertension

Links